Real-World Noninferiority Assessment of Two Filgrastim Biosimilars in Patients Receiving Myelosuppressive Chemotherapy.

Ye Ji LeeThomas Delate Rita L HuiKim LeCatherine Pham

Published in: JCO oncology practice (2024)

Among patients with select solid tumors receiving myelosuppressive chemotherapy, severe neutropenia outcomes were comparable between filgrastim-aafi and filgrastim-sndz biosimilars. Findings from this study may support utilization of different filgrastim biosimilars in clinical practice.

Keyphrases

chemotherapy induced
clinical practice
locally advanced
type diabetes
squamous cell carcinoma
metabolic syndrome
radiation therapy
adipose tissue
skeletal muscle
insulin resistance